-Livemint.com Govt plans to?help firms revamp manufacturing units,?refurbish machinery,?ensure subsidized power in bid to produce drugs such as penicillin at competitive rates New Delhi: The Department of Pharmaceuticals (DoP), during a meeting on Wednesday, urged pharma companies to strive for self-sufficiency in critical drugs like penicillin, rifampicin and insulin, in a sign of government concern over India’s dependence on Chinese imports. A large number of so-called active pharmaceutical ingredients (APIs), or bulk drugs,...

-The Times of India NEW DELHI: In a move to ensure efficacy of medicines sold in India, the drug regulator has made it mandatory for companies to include Indian patients in global clinical trials if they want to market in India a new drug developed outside the country. The decision was taken in a recent technical committee meeting, headed by director general of health services Jagdish Prasad. The committee, which was formed...

-Livemint.com India’s new industrial policy is an opportunity to address the problems of low R&D spending and tough competition from cheap Chinese imports The framing of the new industrial policy should be seen as an opportunity to chart a meaningful path for industry’s role in India’s development. The recently released discussion paper by the department of industrial policy and promotion mentions two points that need to be examined closely to grasp the...

-TheWire.in The negotiator’s comments were non-committal but indicated that for now, the RCEP talks have not yet moved decisively into a TRIP-plus scenario. The chief negotiator for New Zealand, at the Asia trade pact talks in Hyderabad this week, made pointed reference to TRIPS-plus (Trade-Related Aspects of Intellectual Property Rights) provisions, saying that while the TRIPS agreement on intellectual property rights was sufficient, it was up to the countries to analyse whether...

-TheWire.in The government’s premier policy-formulating agency recently recommended measures to deregulate the pharmaceutical sector and make essential medicines more expensive. New Delhi: Even as the prime minister repeatedly expresses his commitment to providing affordable medicines in the country, it appears that the NITI Aayog and the Department of Pharmaceuticals (DoP) may be working in an opposing direction. Documents between October 2016 and April 2017 show the intention of various government arms to...